LifeMD announces new, lower cash-pay price for GLP-1 medications

LifeMD (LFMD) announced a new, lower cash-pay price for GLP-1 medications, Wegovy and Ozempic, made possible through its ongoing collaboration with Novo Nordisk (NVO). LifeMD will now offer the 0.25 mg and 0.5 mg doses at $199 per month-the lowest cash-pay pricing available nationwide-for two fills for new patients. The offering is designed to support patients who pay out of pocket. “We are proud to continue offering the most competitive cash-pay pricing for GLP-1 therapies in America,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. “Our goal remains the same: to maximize access to safe, FDA-approved medications through a frictionless virtual care experience that delivers long-term and sustainable weight loss and health benefits for our patients.”